Impact of low dose atorvastatin on development of new-onset diabetes mellitus in Asian population

Three-year clinical outcomes

Ji Young Park, Seung-Woon Rha, ByoungGeol Choi, Jae Woong Choi, Sung Kee Ryu, Seunghwan Kim, Yung Kyun Noh, Se Yeon Choi, Raghavender Goud Akkala, Hu Li, Jabar Ali, Shaopeng Xu, Harris Abdullah Ngow, Jae Joong Lee, Gwang No Lee, JiBak Kim, Sunki Lee, Jin Oh Na, Cheol Ung Choi, Hong Euy Lim & 5 others Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: High dose atorvastatin is known to be associated with new onset diabetes mellitus (NODM) in patients with high risk for developing diabetes mellitus (DM). However, low dose atorvastatin is more commonly used as compared with high dose atorvastatin. The aim of this study is to investigate the impact of low dose atorvastatin (LDA, 10 mg or 20 mg) on the development of NODM up to three years in Asian patients. Methods: From January 2004 to September 2009, we investigated a total of 3566 patients who did not have DM. To adjust for potential confounders, a propensity score matching (PSM) analysis was performed using the logistic regression model. After PSM(C-statistics: 0.851), a total of 818 patients (LDA group, n=409 patients and control group, n = 409 patients) were enrolled for analysis. Results: Before PSM, the cumulative incidence of NODM(5.8% vs. 2.1%, p b 0.001),myocardial infarction (0.5% vs. 0.1%, p-value = 0.007), and major adverse cardio-cerebral event (MACCE, 1.8% vs. 0.7%, p-value = 0.012) at three-years were higher in the LAD group. However, after PSM, there was a trend toward higher incidence of NODM (5.9% vs. 3.2%, p = 0.064) in the LDA group, but the incidence of MACCE (1.2% vs. 1.5%, p-value = 1.000) was similar between the two groups. In multivariable analysis, the LDA administration was tended to be an independent predictor of NODM (OR: 1.99, 95% CI: 1.00-3.98, p-value 0.050). Conclusions: In this study, the use of LDA tended to be a risk factor for NOD Min Asian patients and reduced clinical events similar to the control group. However, large-scale randomized controlled trials will be needed to get the final conclusion.

Original languageEnglish
Pages (from-to)502-506
Number of pages5
JournalInternational Journal of Cardiology
Volume184
Issue number1
DOIs
Publication statusPublished - 2015

Fingerprint

Diabetes Mellitus
Propensity Score
Population
Incidence
Logistic Models
Control Groups
Atorvastatin Calcium
Randomized Controlled Trials
Myocardial Infarction

Keywords

  • Atorvastatin
  • New onset diabetes mellitus

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Impact of low dose atorvastatin on development of new-onset diabetes mellitus in Asian population : Three-year clinical outcomes. / Park, Ji Young; Rha, Seung-Woon; Choi, ByoungGeol; Choi, Jae Woong; Ryu, Sung Kee; Kim, Seunghwan; Noh, Yung Kyun; Choi, Se Yeon; Akkala, Raghavender Goud; Li, Hu; Ali, Jabar; Xu, Shaopeng; Ngow, Harris Abdullah; Lee, Jae Joong; Lee, Gwang No; Kim, JiBak; Lee, Sunki; Na, Jin Oh; Choi, Cheol Ung; Lim, Hong Euy; Kim, Jin Won; Kim, Eung Ju; Park, Chang Gyu; Seo, Hong Seog; Oh, Dong Joo.

In: International Journal of Cardiology, Vol. 184, No. 1, 2015, p. 502-506.

Research output: Contribution to journalArticle

Park, JY, Rha, S-W, Choi, B, Choi, JW, Ryu, SK, Kim, S, Noh, YK, Choi, SY, Akkala, RG, Li, H, Ali, J, Xu, S, Ngow, HA, Lee, JJ, Lee, GN, Kim, J, Lee, S, Na, JO, Choi, CU, Lim, HE, Kim, JW, Kim, EJ, Park, CG, Seo, HS & Oh, DJ 2015, 'Impact of low dose atorvastatin on development of new-onset diabetes mellitus in Asian population: Three-year clinical outcomes', International Journal of Cardiology, vol. 184, no. 1, pp. 502-506. https://doi.org/10.1016/j.ijcard.2015.03.047
Park, Ji Young ; Rha, Seung-Woon ; Choi, ByoungGeol ; Choi, Jae Woong ; Ryu, Sung Kee ; Kim, Seunghwan ; Noh, Yung Kyun ; Choi, Se Yeon ; Akkala, Raghavender Goud ; Li, Hu ; Ali, Jabar ; Xu, Shaopeng ; Ngow, Harris Abdullah ; Lee, Jae Joong ; Lee, Gwang No ; Kim, JiBak ; Lee, Sunki ; Na, Jin Oh ; Choi, Cheol Ung ; Lim, Hong Euy ; Kim, Jin Won ; Kim, Eung Ju ; Park, Chang Gyu ; Seo, Hong Seog ; Oh, Dong Joo. / Impact of low dose atorvastatin on development of new-onset diabetes mellitus in Asian population : Three-year clinical outcomes. In: International Journal of Cardiology. 2015 ; Vol. 184, No. 1. pp. 502-506.
@article{e9a67cd085d94497939070af820aaa7f,
title = "Impact of low dose atorvastatin on development of new-onset diabetes mellitus in Asian population: Three-year clinical outcomes",
abstract = "Background: High dose atorvastatin is known to be associated with new onset diabetes mellitus (NODM) in patients with high risk for developing diabetes mellitus (DM). However, low dose atorvastatin is more commonly used as compared with high dose atorvastatin. The aim of this study is to investigate the impact of low dose atorvastatin (LDA, 10 mg or 20 mg) on the development of NODM up to three years in Asian patients. Methods: From January 2004 to September 2009, we investigated a total of 3566 patients who did not have DM. To adjust for potential confounders, a propensity score matching (PSM) analysis was performed using the logistic regression model. After PSM(C-statistics: 0.851), a total of 818 patients (LDA group, n=409 patients and control group, n = 409 patients) were enrolled for analysis. Results: Before PSM, the cumulative incidence of NODM(5.8{\%} vs. 2.1{\%}, p b 0.001),myocardial infarction (0.5{\%} vs. 0.1{\%}, p-value = 0.007), and major adverse cardio-cerebral event (MACCE, 1.8{\%} vs. 0.7{\%}, p-value = 0.012) at three-years were higher in the LAD group. However, after PSM, there was a trend toward higher incidence of NODM (5.9{\%} vs. 3.2{\%}, p = 0.064) in the LDA group, but the incidence of MACCE (1.2{\%} vs. 1.5{\%}, p-value = 1.000) was similar between the two groups. In multivariable analysis, the LDA administration was tended to be an independent predictor of NODM (OR: 1.99, 95{\%} CI: 1.00-3.98, p-value 0.050). Conclusions: In this study, the use of LDA tended to be a risk factor for NOD Min Asian patients and reduced clinical events similar to the control group. However, large-scale randomized controlled trials will be needed to get the final conclusion.",
keywords = "Atorvastatin, New onset diabetes mellitus",
author = "Park, {Ji Young} and Seung-Woon Rha and ByoungGeol Choi and Choi, {Jae Woong} and Ryu, {Sung Kee} and Seunghwan Kim and Noh, {Yung Kyun} and Choi, {Se Yeon} and Akkala, {Raghavender Goud} and Hu Li and Jabar Ali and Shaopeng Xu and Ngow, {Harris Abdullah} and Lee, {Jae Joong} and Lee, {Gwang No} and JiBak Kim and Sunki Lee and Na, {Jin Oh} and Choi, {Cheol Ung} and Lim, {Hong Euy} and Kim, {Jin Won} and Kim, {Eung Ju} and Park, {Chang Gyu} and Seo, {Hong Seog} and Oh, {Dong Joo}",
year = "2015",
doi = "10.1016/j.ijcard.2015.03.047",
language = "English",
volume = "184",
pages = "502--506",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Impact of low dose atorvastatin on development of new-onset diabetes mellitus in Asian population

T2 - Three-year clinical outcomes

AU - Park, Ji Young

AU - Rha, Seung-Woon

AU - Choi, ByoungGeol

AU - Choi, Jae Woong

AU - Ryu, Sung Kee

AU - Kim, Seunghwan

AU - Noh, Yung Kyun

AU - Choi, Se Yeon

AU - Akkala, Raghavender Goud

AU - Li, Hu

AU - Ali, Jabar

AU - Xu, Shaopeng

AU - Ngow, Harris Abdullah

AU - Lee, Jae Joong

AU - Lee, Gwang No

AU - Kim, JiBak

AU - Lee, Sunki

AU - Na, Jin Oh

AU - Choi, Cheol Ung

AU - Lim, Hong Euy

AU - Kim, Jin Won

AU - Kim, Eung Ju

AU - Park, Chang Gyu

AU - Seo, Hong Seog

AU - Oh, Dong Joo

PY - 2015

Y1 - 2015

N2 - Background: High dose atorvastatin is known to be associated with new onset diabetes mellitus (NODM) in patients with high risk for developing diabetes mellitus (DM). However, low dose atorvastatin is more commonly used as compared with high dose atorvastatin. The aim of this study is to investigate the impact of low dose atorvastatin (LDA, 10 mg or 20 mg) on the development of NODM up to three years in Asian patients. Methods: From January 2004 to September 2009, we investigated a total of 3566 patients who did not have DM. To adjust for potential confounders, a propensity score matching (PSM) analysis was performed using the logistic regression model. After PSM(C-statistics: 0.851), a total of 818 patients (LDA group, n=409 patients and control group, n = 409 patients) were enrolled for analysis. Results: Before PSM, the cumulative incidence of NODM(5.8% vs. 2.1%, p b 0.001),myocardial infarction (0.5% vs. 0.1%, p-value = 0.007), and major adverse cardio-cerebral event (MACCE, 1.8% vs. 0.7%, p-value = 0.012) at three-years were higher in the LAD group. However, after PSM, there was a trend toward higher incidence of NODM (5.9% vs. 3.2%, p = 0.064) in the LDA group, but the incidence of MACCE (1.2% vs. 1.5%, p-value = 1.000) was similar between the two groups. In multivariable analysis, the LDA administration was tended to be an independent predictor of NODM (OR: 1.99, 95% CI: 1.00-3.98, p-value 0.050). Conclusions: In this study, the use of LDA tended to be a risk factor for NOD Min Asian patients and reduced clinical events similar to the control group. However, large-scale randomized controlled trials will be needed to get the final conclusion.

AB - Background: High dose atorvastatin is known to be associated with new onset diabetes mellitus (NODM) in patients with high risk for developing diabetes mellitus (DM). However, low dose atorvastatin is more commonly used as compared with high dose atorvastatin. The aim of this study is to investigate the impact of low dose atorvastatin (LDA, 10 mg or 20 mg) on the development of NODM up to three years in Asian patients. Methods: From January 2004 to September 2009, we investigated a total of 3566 patients who did not have DM. To adjust for potential confounders, a propensity score matching (PSM) analysis was performed using the logistic regression model. After PSM(C-statistics: 0.851), a total of 818 patients (LDA group, n=409 patients and control group, n = 409 patients) were enrolled for analysis. Results: Before PSM, the cumulative incidence of NODM(5.8% vs. 2.1%, p b 0.001),myocardial infarction (0.5% vs. 0.1%, p-value = 0.007), and major adverse cardio-cerebral event (MACCE, 1.8% vs. 0.7%, p-value = 0.012) at three-years were higher in the LAD group. However, after PSM, there was a trend toward higher incidence of NODM (5.9% vs. 3.2%, p = 0.064) in the LDA group, but the incidence of MACCE (1.2% vs. 1.5%, p-value = 1.000) was similar between the two groups. In multivariable analysis, the LDA administration was tended to be an independent predictor of NODM (OR: 1.99, 95% CI: 1.00-3.98, p-value 0.050). Conclusions: In this study, the use of LDA tended to be a risk factor for NOD Min Asian patients and reduced clinical events similar to the control group. However, large-scale randomized controlled trials will be needed to get the final conclusion.

KW - Atorvastatin

KW - New onset diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84933556998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933556998&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2015.03.047

DO - 10.1016/j.ijcard.2015.03.047

M3 - Article

VL - 184

SP - 502

EP - 506

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 1

ER -